<DOC>
	<DOCNO>NCT00293839</DOCNO>
	<brief_summary>The purpose study compare efficacy DITROPANÂ® XL ( oxybutynin chloride ) Extended-Release Tablets DETROLÂ® LA ( tolterodine tartrate extended-release capsule ) reduction urge urinary incontinence episodes 12-week treatment period patient overactive bladder . The secondary objective compare tolerability DITROPANÂ® XL ( oxybutynin chloride ) DETROLÂ® LA ( tolterodine tartrate ) 12-week treatment period .</brief_summary>
	<brief_title>Efficacy Tolerability DITROPAN XL ( Oxybutynin Chloride ) Versus DETROL LA ( Tolterodine Tartrate ) Treatment Overactive Bladder</brief_title>
	<detailed_description>The objective study compare efficacy tolerability DITROPAN® XL 10 mg once-daily DETROL® LA 4 mg once-daily reduction urge urinary incontinence episode female patient overactive bladder . This multicenter , randomize , double-blind , parallel-group study two active treatment . Screened patient qualify study base information obtain seven consecutive 24-hour urinary diary complete Baseline Week , eligibility criterion . Qualifying patient receive 12 week treatment DITROPAN® XL DETROL® LA , clinical visit end Weeks 2 , 4 , 8 , 12 . Safety evaluation study include collection adverse event , laboratory test include blood chemistry urinalysis , physical examination , vital sign ( blood pressure heart rate ) post-void residual urine volume . Over-encapsulated DITROPAN® XL , 10 mg tablet once-daily mouth over-encapsulated DETROL® LA , 4 mg capsule daily mouth . The treatment phase study run 12 week .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Participants able differentiate urinary incontinence episode associated urgency urinary incontinence episode associate urgency 7 day baseline period 21 60 urge urinary incontinence ( UrgeUI ) episodes , great number UrgeUI episodes urinary incontinence associate urge , average 10 void per 24 hour good general health determine medical history , physical examination ( general , genital , pelvic , rectal ) , laboratory test urinalysis take antihypertension medication , must stable dose childbearing potential , practice acceptable method birth control , must negative pregnancy test Visit 2 Visit 3 Participants know , treatable genitourinary condition ( identify history examination ) may cause incontinence ( e.g. , urinary tract infection , interstitial cystitis , urinary tract obstruction , urethral diverticulum , bladder tumor , bladder stone ) give birth pelvic , vaginal bladder surgery le 6 month study enrollment second postvoid residual urine volume &gt; 150 mL time screening ( determined abdominal ultrasound ) significant medical problem organ abnormality place risk participate study significant risk develop complete urinary retention significant impairment liver kidney determine laboratory assessment hematuria ( red blood cell microscopic urinalysis )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>bladder</keyword>
	<keyword>overactive</keyword>
</DOC>